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ABSTRACT
Objectives: Lower pill burden leads to improved
antiretroviral therapy (ART) adherence among HIV patients.
Simpler dosing regimens have not been widely explored in
real-world populations. We retrospectively assessed ART
adherence, all-cause hospitalisation risk and costs, and
other healthcare utilisation and costs in Medicaid enrollees
with HIV treated with ART as a once-daily single-tablet
regimen (STR) or two or more pills per day (2+PPD).
Design: Patients with an HIV diagnosis from 2005 to 2009
receiving complete ART (ie, two nucleoside/nucleotide
reverse transcriptase inhibitors plus a third agent) for
≥60 days as STR or 2+PPD were selected and followed
until the first of (1) discontinuation of the complete ART, (2)
loss of enrolment or (3) end of database. Adherence was
measured using the medication possession ratio. Monthly
all-cause healthcare utilisation and costs were observed
from regimen initiation until follow-up end.
Results: Of the 7381 patients who met inclusion criteria,
1797 were treated with STR and 5584 with 2+PPD. STR
patients were significantly more likely to reach 95%
adherence and had fewer hospitalisations than 2+PPD
patients (both p<0.01). STR patients had mean (SD) total
monthly costs of $2959 ($4962); 2+PPD patients had
$3544 ($5811; p<0.001). Hospital costs accounted for
53.8% and pharmacy costs accounted for 32.5% of this
difference. Multivariate analyses found that STR led to a
23% reduction in hospitalisations and a 17% reduction in
overall healthcare costs. ART adherence appears to be a
key mechanism mediating hospitalisation risk, as patients
with ≥95% adherence (regardless of regimen type) had a
lower hospitalisation rate compared with <95% adherence.
Conclusions:While it was expected that STR patients
would have lower pharmacy costs, we also found that STR
patients had fewer hospitalisations and lower hospital
costs than 2+PPD patients, resulting in significantly lower
total healthcare costs for STR patients.
INTRODUCTION
The 2012 Department of Health and Human
Services (DHHS) guidelines state that there
are four preferred regimens for initiating HIV
treatment in adults. Furthermore, there are
multiple alternatives to these four regimens.1
Patients and their treating physicians can
choose from among these four preferred regi-
mens, using the criteria of greatest efﬁcacy,
safety and simplicity. The latter category is
important because regimen simplicity is asso-
ciated with greater long-term adherence. For
example, all four preferred regimens are con-
structed with a relatively low pill burden (ie,
between one and four tablets per day), and
three of the four regimens have once-daily
dosing. While randomised trials have com-
pared the components of some of these four
regimens with each other, until now no studies
have compared the four regimens with each
other as they are prescribed (ie, in a real-world
setting), given that these study trials have been
blinded.2 3
ARTICLE SUMMARY
Article focus
▪ To assess the association between a
single-tablet-per-day antiretroviral therapy (ART)
regimen (STR) and treatment adherence, all-
cause hospitalisation risk and other all-cause
healthcare utilisation and costs in a large popula-
tion of Medicaid enrollees in the USA who
received treatment for HIV infection.
Key messages
▪ Patients who received ART as a single-pill per
day were significantly more likely to be highly
adherent (≥95%) to therapy than patients who
received multiple-pill regimens.
▪ Improved adherence among patients treated with
STR conferred a lower risk of hospitalisation.
▪ The use of an STR may reduce healthcare costs
as well as patient morbidity by decreasing hospi-
talisation rates, which were higher in patients
with less-than-complete medication adherence.
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Adherence to antiretroviral therapy (ART) is essential
for achieving durable clinical outcomes in patients with
HIV. Patients with inadequate adherence to ART are at
an increased risk for incomplete viral suppression, and
unless a new suppressive regimen is quickly constructed
to re-establish virological suppression, viraemia is asso-
ciated with an increased risk of disease progression and
death.4–8 It has been suggested that an ART adherence
rate of at least 95% is required to achieve a lower risk of
virological failure, fewer hospital days and reduced mor-
bidity and mortality in patients with HIV,8 9 although
one previous study indicated that viral suppression may
be possible at less than 95% adherence.10 In the past
several years, the availability of ﬁxed-dose combinations
and agents with prolonged half-lives have simpliﬁed pill
burden and thus increased regimen adherence.1 11
Several clinical trials and cohort studies support the con-
clusion that once-daily single-tablet regimens (STR) can
lead to signiﬁcantly improved adherence, patient satis-
faction and virological outcomes.12–15 For example,
among the homeless or marginally housed patients,
those receiving an ART regimen composed of a single
tablet per day had better virological outcomes and a
26% increase in adherence than patients receiving other
multipill regimens.15 One recently published study ana-
lysing a claims database noted that compared with
various multipill regimens, an STR was associated with
increased adherence (as determined by pharmacy reﬁll
data). Furthermore, the increased likelihood of
complete adherence was associated with a 25% decrease
in the rate of hospitalisation.16
In this study, we sought to assess how robust these ﬁnd-
ings were by analysing similar metrics in a separate data
set. The primary objective of this retrospective database
analysis was to assess the association between a
single-tablet-per-day ART regimen and treatment adher-
ence, all-cause hospitalisation risk and total all-cause
healthcare costs in a large population of Medicaid enrol-
lees in the USA who received treatment for HIV infec-
tion. The secondary objective of this study was to
examine the association between STR and other types of
all-cause healthcare utilisation (emergency department,
pharmacy, outpatient and other service types) and costs.
METHODS
Data for this analysis were taken from the MarketScan
Medicaid Multi-State Database, which contains health-
care claims from approximately 30 million Medicaid
enrollees from 11 geographically dispersed states. The
database includes patient-level demographics; periods of
Medicaid enrolment; primary and secondary diagnoses
and detailed information about hospitalisations and
therapeutic procedures, inpatient and outpatient phys-
ician services and prescription drug use. Each medical
and pharmacy claim in the database also includes ori-
ginal cost information, which represents direct paid
amounts (in US dollars) from Medicaid to providers for
each service or prescription. In compliance with the
Health Insurance and Portability and Accountability Act
of 1996, all data were de-identiﬁed to protect the privacy
of individual patients, physicians and hospitals. As the
data were retrospective, pre-existing and de-identiﬁed,
RTI International’s institutional review board (IRB)
determined that this study met all criteria for exemption
from requirements of patient consent.
Patients were selected for inclusion if they received at
least one HIV or AIDS diagnosis (International
Classiﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation
(ICD-9-CM) code 042.xx) between 1 June 2006 and
31 December 2009. Patients also were required to have
evidence of receipt of a complete ART regimen, deﬁned
as two nucleoside/nucleotide reverse transcriptase inhi-
bitors plus a third agent (ie, another nucleoside/nucleo-
tide reverse transcriptase inhibitor, a non-nucleoside/
nucleotide reverse transcriptase inhibitor, a protease
inhibitor (PI), a chemokine receptor R5 antagonist or
an integrase inhibitor). The ﬁrst date of receipt of a
complete regimen was termed the index date. ART
agents were identiﬁed in the claims database by using
National Drug Codes associated with relevant generic
and brand names. Patients also were required to remain
on the complete ART regimen for at least 60 days follow-
ing their index dates and to have evidence of continu-
ous enrolment in Medicaid during this period. To assess
treatment-naïve versus experienced status and baseline
comorbidities, patients were required to have at least
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This retrospective analysis used pharmacy refill dates as the
best available proxy for pill-taking behaviour; one advantage to
this method is that we can identify those patients who may
not have had all or some of their medications available on any
given date based on an analysis of the timing in between
refills, which also notes the amount of medication dispensed
each time.
▪ Rates of hospitalisation and correlates of hospitalisation also
were assessed from these claims data and should be highly
accurate, as should measures of overall monthly healthcare
utilisation and costs.
▪ While our prescription claims-based measure of adherence
has been found to be a valid proxy for actual medication-
taking behaviour, we had no measure of actual patient adher-
ence (ie, daily ingestion/consumption) to the prescriptions
they filled.
▪ As we did not randomise patients to the two different treat-
ment regimens, we cannot exclude unmeasured confounding
factors that may have influenced our outcomes; although we
attempted to control for some of these variables through the
use of multivariable models that included some of these
factors (substance abuse and psychiatric diagnoses), residual
confounding may remain.
▪ We had no laboratory results from patients and thus cannot
confirm the degree of virological suppression obtained across
the regimens.
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6 months of preindex date Medicaid enrolment, with
enrolment information available from 1 January 2006
(ie, 6 months before the earliest possible index date).
Patients were grouped into two mutually exclusive
cohorts according to the daily pill count of their com-
plete ART regimen. Patients were assigned to the STR
cohort if they received an ART regimen consisting of a
single tablet (ie, an STR) at any point during the selec-
tion window, regardless of prior or subsequent use of
other regimens. At the time of this study, only coformu-
lated tenofovir/emtricitabine/efavirenz was available as
an STR. Patients were assigned to the
two-or-more-pills-per-day (2+PPD) cohort if they received
a regimen consisting of 2+PPD during the selection
window and if they did not receive an STR at any point
during that time.
Patients were followed from the start of their complete
ART regimen (ie, after 1 June 2006, the study index
date) until the earliest date of regimen discontinuation,
disenrolment from the health plan or the end of the
database (ie, 31 March 2009). Furthermore, patients
receiving 2+PPD were allowed to change medications
comprising the regimen, provided that the patients con-
tinued to receive a combination of agents that could still
be classiﬁed as a complete 2+PPD regimen. Patients
receiving STR were followed for as long as they
remained on STR. Discontinuation was deﬁned as
60 consecutive days in which no reﬁlls were observed for
any component of the regimen. Women with an
ICD-9-CM diagnosis code indicating a pregnancy during
the follow-up period were excluded from the analysis
because the one available STR is not recommended for
pregnant women, and hospitalisations for labour and
delivery may have biased results in favour of STR.
Patient characteristics measured at the index date
included age, sex and ART classes received (ie, nucleo-
side/nucleotide reverse transcriptase inhibitors, non-
nucleoside/nucleotide reverse transcriptase inhibitors,
PIs, ritonavir boosting therapy or other therapies). The
presence of comorbid medical conditions other than
HIV or AIDS were assessed during the 6-month preindex
period using an established algorithm, the Charlson
Comorbidity Index (CCI) score.17 This score is made up
of 17 comorbidities (deﬁned by the ICD-9-CM diagnosis
and procedure codes), such as myocardial infarction
and chronic pulmonary disease, which are weighted to
correspond to the severity of the comorbid condition of
interest. A higher comorbidity score represents a higher
overall comorbidity burden during the preindex period.
Additionally, the incidence of other concomitant mental
disorders (ICD-9-CM codes 306.xx through 319.xx) and
drug and alcohol abuse (ICD-9-CM codes 292.xx and
303.xx through 305.xx) during the 6-month preindex
period was also assessed.
Medication adherence was assessed using the medica-
tion possession ratio (MPR), which has been shown to
be the most widely adopted measure (57% of all
studies) in published claims-based analyses of
medication adherence18 and has been used in studies of
ART adherence among individuals with HIV.19 MPR,
which is a proxy for reﬁll compliance, generally mea-
sures the proportion of the ART-exposure period in
which supply was maintained for all ART components
comprising the regimen. Speciﬁcally, MPR was calcu-
lated as the number of ﬁlled prescription days for all
ART regimen components (using the days supplied in
the pharmacy claims) divided by the number of days
from the ﬁrst observed prescription in the regimen
through the earliest of either the exhaustion of the days
supplied of the last observed prescription or the end of
follow-up. For each patient in our study, MPR was calcu-
lated over the period in which the patient remained on
his or her ART regimen. For patients in the 2+PPD
cohort, late reﬁlls and resulting days of missing supply
for one or more ART components were all factored
against their adherence measurements. For example,
patients in the 2+PPD cohort with a supply for only one
of the ART components on a given day were considered
to have zero adherence for that day. In addition to
reporting the mean (SD) MPR achieved, we also
reported the numbers and percentages of patients
achieving various adherence thresholds (ie, MPRs of
1.0–0.95, 0.94–0.90, 0.89–0.85 and 0.84–0.80, corre-
sponding to 100–95%, 94–90%, 89–85% and 84–80%
adherence, respectively).
To further understand adherence to ART regimens,
for each patient in the 2+PPD cohort, complete (ie,
having a complete regimen), partial (ie, receiving some
but not all components of a complete regimen) and no
medication days also were assessed. Speciﬁcally, we
reported the percentage of days that each patient had
complete, partial and no medications available, along
with the mean number of days that the patient had com-
plete, partial and no medications. Additionally, we also
reported the maximum number of consecutive days the
patient had either an incomplete regimen or no medica-
tions available.
Hospitalisations were identiﬁed from the claims data-
base using relevant place of service codes. Hospitalisations
were observed from the index date until the earliest date
of regimen discontinuation, end of enrolment in the
health plan or end of the database. The number and per-
centage of patients with at least one hospitalisation were
reported, along with the mean (SD) number of hospitali-
sations and the mean (SD) number of inpatient days.
Furthermore, we compared and reported the number of
hospitalisations per 100 patient-years, along with the rate
ratios and 95% CIs, for both cohorts as well as by adher-
ence status (at least 95% vs less than 95%).
For each patient, overall healthcare utilisation and
associated costs were aggregated across all encounters,
regardless of reason, that were observed during the
follow-up period; we reported these costs by average and
per-month amounts. The following categories of overall
healthcare utilisation and costs were evaluated and
reported: inpatient, emergency department, ofﬁce visit,
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home health visit, laboratory service, pharmacy, other
outpatient care and total. For each category of overall
healthcare, the number and percentage of patients, the
mean (SD) number of visits per month, and monthly
per-patient costs were reported. Additionally, for patients
with an inpatient visit, the average number of inpatient
days per month among patients with at least one stay
during follow-up also was reported. All cost data, which
represented payments incurred by the Medicaid system,
were standardised at the claim level to 2010 US dollars
using the medical care component of the US Consumer
Price Index.
All analyses were carried out using SAS (V.9; Cary,
North Carolina, USA) statistical software. Descriptive
analyses were conducted for all outcome measures and
included means and SDs for continuous variables of
interest (eg, MPR) and frequency distributions of cat-
egorical variables of interest (eg, geographic region). All
descriptive analyses were stratiﬁed by cohort. Healthcare
costs were updated to 2010 US dollars using the medical
care component of the consumer price index.
A generalised linear model with a log link and a
Poisson distribution was estimated to assess the relation-
ship between the number of pills per day and the
number of hospitalisations observed during follow-up.
The dependent variable was a count of hospitalisations
during exposure to the ART regimen. Additionally, a
generalised linear model with a log link and a negative
binomial distribution were estimated to assess monthly
healthcare costs, adjusted for the patient and treatment
characteristics. The dependent variables were monthly
total costs and monthly total costs excluding pharmacy
costs. For both models, based on a previous work by Sax
et al,16 independent variables included the following:
treatment regimen received (ie, STR vs 2+PPD), age,
sex, CCI score, treatment-naïve status, preindex presence
of mental health disorders, preindex presence of
alcohol or drug abuse disorders, length of follow-up (in
days, hospital model only), and whether or not the
patient met a 0.95 adherence threshold (cost model
only). For the hospital model, incidence rate ratios
(IRRs) were reported for all covariates, along with the
mean predicted number of hospitalisations for patients
receiving an STR versus patients receiving a 2+PPD. For
the cost model, adjusted predicted mean costs were
reported.
RESULTS
A total of 7381 patients met the selection criteria (ﬁgure 1).
Of these, 5584 patients (75.7%) received their ART
regimen as 2+PPD; 1797 patients (24.3%) received their
ARTregimen as an STR. On average, patients were approxi-
mately 42 years of age. Approximately 46% of patients were
female (table 1). Across both cohorts, the average CCI
score was approximately the same (mean (SD) 0.67 (1.38)
among patients receiving an STR and 0.65 (1.36) among
patients receiving 2+PPD). Furthermore, the incidence of
concomitant mental disorders and drug and alcohol abuse
diagnoses did not vary substantially by cohort. Patients
receiving an STR had a mean regimen duration of
348 days; this was approximately 2.8 months shorter than
the mean regimen duration of 433 days observed for
patients receiving 2+PPD. Forty-seven per cent of patients
receiving an STR were treatment naïve, compared with
24.5% of patients receiving 2+PPD.
Patients receiving an STR had signiﬁcantly better adher-
ence than patients receiving 2+PPD (table 2).
Approximately 25.3% of patients receiving an STR
achieved 95% adherence or greater, compared with 17.4%
of patients receiving 2+PPD (p≤0.0001). Mean (SD) MPR
was 0.84 (0.14) among patients receiving an STR and 0.80
(0.15) among patients receiving 2+PPD (table 2). Patients
in the 2+PPD cohort received a complete regimen for
80.3% of the follow-up period (mean (SD) 361.9 (315.0)
days), a partial regimen for 5.6% of the follow-up period
(mean (SD) 22.2 (45.6) days), and no available medica-
tions for 14.1% of the follow-up period (mean (SD) 49.4
(57.1) days; table 3). Alternatively, patients in the STR
cohort received a complete regimen for 84.4% of the
follow-up period (mean (SD) 299.4 (234.6) days) and no
available medications for 15.6% of the follow-up period
(mean (SD) 48.8 (54.2) days), which was a similar percent-
age of days to patients receiving 2+PPD. Patients receiving
an STR had, on average, a maximum of 19.5 (SD 15.9)
consecutive days without a complete regimen (ie, either a
partial regimen or no medications available); patients
receiving 2+PPD had, on average, a maximum of 23.9 (SD
16.7) consecutive days without a complete regimen.
Among patients receiving an STR, 21% had at least
one hospitalisation, compared with 24.4% of patients
receiving 2+PPD (p=0.003; table 4). Among patients
with a hospitalisation, those receiving an STR had
numerically similar, although signiﬁcantly fewer, hospita-
lisations over all available follow-up, when compared
with patients receiving 2+PPD (mean (SD) 1.9 (1.6)
among patients receiving an STR vs 2.1 (2.2) among
patients receiving 2+PPD; p=0.001).
The multivariate Poisson regression model showed
that receiving an STR was associated with a signiﬁcantly
lower hospitalisation rate than receiving the 2+PPD
regimen (IRR=0.8457; p<0.001; table 5). When the
received regimen type was controlled for, we found that
patients were signiﬁcantly more likely to be hospitalised
if they had the following characteristics: a concomitant
mental disorder diagnosis (vs no concomitant mental
disorder diagnosis; IRR=1.2917; p<0.001), a concomitant
drug or alcohol abuse diagnosis (vs no concomitant
drug or alcohol abuse diagnosis; IRR=2.0357; p<0.001),
a CCI score greater than 1 (IRR increased with increas-
ing CCI score, from 2.3779 among patients with a CCI
between 1 and 2 to 2.6432 among patients with a CCI
greater than 3; all p<0.001), were female (vs male;
IRR=1.1069; p=0.003), or were older than 35 years (vs
younger than 35 years; IRR increased with increasing
age, up to 54 years, from 1.2482 among patients aged
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35–44 years to 1.555 among patients aged 45–54 years;
both p<0.1). Additionally, the likelihood of a hospitalisa-
tion increased slightly with each additional day of
follow-up (IRR=1.0013; p<0.0001). Finally, being treat-
ment naïve prior to the index date was predictive of an
approximately 13% higher hospitalisation rate as com-
pared with being treatment experienced (IRR=1.1270;
p=0.0033).
From the Poisson regression analysis described above,
we found the adjusted rate of hospitalisation to be sig-
niﬁcantly lower for patients receiving an STR than for
patients receiving 2+PPD (ie, 39.5 hospitalisations per
100 patient-years for patients receiving STR vs 51.2 hos-
pitalisations per 100 patient-years for those receiving
2+PPD; ﬁgure 2). These adjusted hospitalisation rates
translated to a 23% lower risk of hospitalisation among
patients receiving an STR, compared with patients
receiving 2+PPD. As shown in ﬁgure 3, adherence status
seems to be a key mechanism mediating hospitalisation
risk as patients with at least 95% adherence (regardless
of regimen type) had a statistically signiﬁcantly lower
hospitalisation rate compared with patients with less
than 95% adherence. Improved adherence among
patients treated with STR therefore appears to confer a
lower risk of hospitalisation and associated costs.
Examining other types of healthcare utilisation, the
percentage of patients with at least one home health
visit was signiﬁcantly lower among patients receiving
STR than for patients receiving 2+PPD (table 4).
Between the two cohorts, no differences were observed
in the percentage of patients with at least one emer-
gency room, ofﬁce visit or laboratory claim. Similarly, no
signiﬁcant differences were found in the number of
emergency room visits, ofﬁce visits, home health visits or
laboratory claims per month. However, patients who
received an STR had signiﬁcantly lower costs per month
associated with inpatient, home health, laboratory, phar-
macy, other and total healthcare than patients receiving
2+PPD. Mean (SD) total healthcare costs per month
were $2959 ($4962) among patients receiving an STR
and $3544 ($5811) among patients receiving 2+PPD;
thus, patients receiving an STR accrued, on average per
month, $585 less than patients receiving 2+PPD
(p<0.001). The largest difference in costs between the
two cohorts was observed for inpatient admissions ($317
more for patients receiving 2+PPD), followed by phar-
macy costs ($187 more for patients receiving 2+PPD).
When monthly healthcare costs were adjusted for
demographic, clinical and treatment characteristics,
patients receiving an STR had monthly total costs aver-
aging $2947; patients receiving 2+PPD had monthly total
costs averaging $3549 (ﬁgure 4). Thus, patients receiv-
ing 2+PPD had $602 more in monthly healthcare costs,
which corresponded to a 17% reduction in costs asso-
ciated with STR. Additionally, when monthly healthcare
costs, excluding pharmacy costs, were adjusted for demo-
graphic, clinical and treatment characteristics, patients
receiving an STR had monthly total costs averaging
Figure 1 Sample selection flow chart.
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$1370; patients receiving 2+PPD had monthly total costs
averaging $1797. Thus, patients receiving 2+PPD had
$427 more in adjusted monthly healthcare costs, which
corresponded to a 23.8% reduction in costs associated
with STR.
DISCUSSION
This retrospective database analysis examined adherence
to ART regimens among patients with HIV infection,
using pharmacy reﬁll dates as the best available proxy
for pill-taking behaviour. One advantage to this method
Table 1 Characteristics of the study sample, by cohort
Characteristic STR (n=1797) 2+PPD (n=5584) p Value
Age (mean (SD)) 41.6 (10.56) 42.32 (11.37) 0.0137
Gender (N, %)
Male 945 52.59 3063 54.85 0.1123
Female 852 47.41 2521 45.15 0.1439
Race (N, %)
White 387 21.54 1221 21.87 0.8893
Black 1187 66.05 3658 65.51 0.6877
Hispanic 18 1.00 82 1.47 0.7844
Other 204 11.35 621 11.12 0.7846
Unknown 1 0.06 2 0.04 0.8766
Basis of medicaid eligibility (N, %)
Aged 1 0.06 8 0.14 0.5634
Disabled 1089 60.60 4071 72.90 <0.0001
Income 583 32.44 1159 20.76 <0.0001
Other 58 3.23 202 3.61 0.8710
Unknown 65 3.62 141 2.53 0.0487
Medicare eligibility (N, %)
Not dually eligible 1791 99.67 5558 99.53 0.9987
Dually eligible 5 0.28 24 0.43 0.6523
Unknown 1 0.05 2 0.04 0.9014
Charlson comorbidity index score, mean (SD) 0.67 (1.38) 0.65 (1.36) 0.5919
Concomitant mental health and substance abuse comorbidities (N, %)
Mental disorders 382 21.26 1340 24.00 0.0456
Drug or alcohol abuse 338 18.81 856 15.33 0.0323
Treatment naïve at index 853 47.47 1366 24.46 <0.0001
Regimen length, mean (SD) 348.17 (259.32) 433.46 (351.50) <0.0001
Index medications (N, %)
NRTI 1797 100.00 5584 100.00 –
NNRTI 1797 100.00 1500 26.86 <0.0001
PI – – 4064 72.78 –
Kaletra at index – – 1633 40.18 –
Boosted PI at index – – 1664 40.94 –
Non-boosted PI at index – – 767 18.87 –
PE – – 1712 30.66 –
Other – – 87 1.56 –
2+PPD, two or more pills per day; NNRTI, non-nucleoside/nucleotide reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse
transcriptase inhibitor; PE, pharmacokinetic enhancer; PI, protease inhibitor; STR, once-daily single-tablet regimen.
Table 2 Adherence to antiretroviral therapy, by cohort
MPR/persistency ratio (N, %)
Cohort
Number of
patients
Mean (SD)
MPR <0.8 0.8–<0.85 0.85–<0.9 0.9–<0.95 0.95–1
STR 1797 0.84 (0.14) 537 29.88% 178 9.91 243 13.52 385 21.42 454 25.26
2+PPD 5584 0.80 (0.15) 2255 40.38 621 11.12 779 13.95 957 17.14 972 17.41
Overall 7381 0.81 (0.15) 2792 37.83 799 10.83 1022 13.85 1342 18.18 1426 19.32
p Value (1 vs 2) <0.0001 <0.0001 0.1491 0.6477 <0.0001 <0.0001
2+PPD, two or more pills per day; MPR, medication possession ratio; STR, once-daily single-tablet regimen.
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is that we can identify those patients who may not have
had all or some of their medications available on any
given date based on an analysis of the timing in between
reﬁlls, which also notes the amount of medication dis-
pensed each time. The rate of hospitalisation and corre-
lates of hospitalisation also were assessed from these
claims data and should be highly accurate, as should the
overall monthly healthcare utilisation and costs.
This analysis largely conﬁrms the previous report from
Sax et al16: we found that patients receiving an STR had
signiﬁcantly better adherence rates than patients receiv-
ing multiple pills per day. Our other ﬁnding was that
Table 4 All-cause average per patient healthcare utilisation and costs, by cohort
Resource used STR (n=1797) 2+PPD (n=5584) p Value
Hospitalisations
Had ≥1 hospital admission (N, %)* 378 21.04 1,365 24.44 0.0031
Number of hospitalisations (overall follow-up) mean (SD)† 1.88 (1.59) 2.1 (2.23) 0.0012
Inpatient days (overall follow-up) mean (SD)† 9.99 (12.33) 12.33 (18.90) 0.0228
Costs per month, mean (SD) $834 ($4480) $1152 ($5212) 0.0203
Emergency room (ER)
Had ≥1 ER visit (N, %)* 903 50.25 2,749 49.23 0.4517
Number of visits per month, mean (SD) 0.97 (3.00) 1.01 (2.99) 0.6107
Costs per month, mean (SD) $45 ($160) $46 ($135) 0.873
Office visits (primary care) (N, %)
Had ≥1 office visit (N, %)* 1509 83.97 4699 84.15 0.8576
Number of visits per month, mean (SD) 1.52 (3.00) 1.43 (2.19) 0.1669
Costs per month, mean (SD) $75 ($229) $70 ($291) 0.5087
Home health (N, %)
Had ≥1 home health visit (N, %)* 504 28.05 1861 33.33 <0.0001
Number of visits per month, mean (SD) 0.64 (3.00) 0.79 (3.16) 0.0625
Costs per month, mean (SD) $47 ($198) $88 ($642) 0.007
Laboratory (N, %)
Had ≥1 lab order (N, %)* 1168 65.00 3530 63.22 0.1722
Number of lab tests per month, mean (SD) 1.24 (2.00) 1.19 (1.69) 0.2962
Costs per month, mean (SD) $52 ($94) $46 ($120) 0.0401
Pharmacy (N, %)
Had ≥1 pharmacy claim (N, %)* 1797 100.00 5584 100.00 –
Number of prescriptions per month, mean (SD) 4.99 (4.00) 6.73 (4.05) <0.0001
Costs per month, mean (SD) $1593 ($1105) $1779 ($1307) <0.0001
OP/ancillary (N, %)
Had ≥1 other outpatient/ancillary visit (N, %)* 1754 97.61 5469 97.94 0.3957
Number of visits per month, mean (SD) 0.15 (0.00) 0.14 (0.13) 0.0078
Costs per month, mean (SD) $313 ($607) $363 ($733) 0.0087
Total healthcare utilisation and costs
Had ≥1 medical visit/encounter (N, %)* 1797 100.00 5584 100.00 –
Number of total encounters per month, mean (SD) 14.69 (14.00) 16.97 (13.72) <0.0001
Costs per month, mean (SD) $2959 ($4962) $3544 ($5811) 0.0001
*Estimated overall available follow-up.
†Among hospitalised patients.
Table 3 Summary of incomplete adherence, by cohort
Adherence characteristic STR (n=1797) 2+PPD (n=5584) p Value
Percentage of days with complete adherence 84.42% 80.37% <0.0001
Percentage of days with partial adherence – 5.56% –
Percentage of days with no ART medications 15.58% 14.07% 0.0356
Complete adherence days, mean (SD) 299.36 (234.56) 361.87 (315.03) <0.0001
Partial adherence days, mean (SD) – 22.24 (45.58) –
Days with no medication available, mean (SD) 48.81 (54.24) 49.35 (57.11) 0.0356
Total follow-up duration, mean (SD) 348.17 (259.31) 433.46 (351.50) <0.0001
Maximum consecutive gap in therapy mean (SD)* 19.48 (15.89) 23.92 (16.67) <0.0001
*Represents either days with a partial regimen or days with no medications.
2+PPD, two or more pills per day; ART, antiretroviral therapy; STR, once-daily single-tablet regimen.
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higher rates of adherence were associated with similar or
lower rates of hospitalisation, regardless of the regimen;
less-than-complete adherence was associated with higher
rates of hospitalisation and overall costs. Thus, multiple-
pill regimens were associated with lower rates of com-
plete adherence and correspondingly higher overall
healthcare costs. We observed a signiﬁcantly higher rate
of hospitalisations occurring in patients receiving
multiple-pill regimens (p<0.001) than in patients receiv-
ing an STR. The greater total healthcare costs were due
to differences in the pharmacy costs of the regimen
components as well as the costs of hospitalisations and
associated care. Therefore, one implication of our ﬁnd-
ings is that choosing a multiple-pill regimen for its cost
alone might inadvertently result in little to no total
healthcare cost-savings for a payer, given the potential
risk of more frequent hospitalisations in patients receiv-
ing multiple-pill regimens.
Similar to previous studies,4 20 we found that patients
who were adherent to therapy were less likely to be hospi-
talised. Our data demonstrated similar rates of
hospitalisations among patients with the highest levels of
complete adherence—at least 95%. This was consistent
across both treatment cohorts. This ﬁnding suggests that
the differences observed in the rates of hospitalisations
across regimens are primarily due to differences in adher-
ence rates between the STR and 2+PPD regimens rather
than any concerns for toxicities. This ﬁnding also may par-
tially address the potential contribution of channelling
bias, a concern with any observational data set. We found
that adherent patients on any regimen have similar rates
of hospitalisation, which suggests that there may not have
been a consistent bias to prescribe to more clinically
immunosuppressed patients or to patients who were at
greater risk for hospitalisation due to other factors than a
multiple-pill regimen. Furthermore, we found that the
outcome of fewer hospitalisations for patients receiving an
STR was consistent when we compared hospitalisation
risks for treatment-naïve patients with hospitalisation risks
for treatment-experienced patients. In the latter group,
the impact of stage of illness prior to treatment would be
lessened, given the impact of prior treatment on improv-
ing pretreatment immunosuppression, with an STR
regimen. Of ﬁnal note regarding channelling bias, previ-
ous analyses of Medicaid beneﬁciaries with HIV have
shown that patients receiving ART are completely non-
adherent (ie, days with no ART supply/coverage on hand)
for approximately 14% of their regimen duration regard-
less of the number of pills in the regimen.21 This ﬁnding
suggests that clinicians are not channelling more adherent
patients to STRs. Together, these data support the observa-
tion that facilitating greater adherence to ART at any stage
of illness may result in reducing hospitalisation risk.
One follow-up question our study ﬁndings raises is
whether the observed reduction in hospitalisation risk
and costs with STR was also due to less prevalent
chronic comorbidities in patients prescribed STR. To
assess this possibility, we replicated key descriptive
Table 5 Predictors of hospitalisation, using multivariate Poisson regression, and controlling for treatment cohort
Poisson count model
Specification: adherence covariate excluded
Parameter
estimate
Incidence rate
ratio p Value
Received an STR (vs 2+PPD regimen) −0.1654 0.8475 0.0001
Female (vs male) 0.1003 1.1069 0.003
Age (vs less than 35) (years)
35–44 0.1016 1.2482 0.0669
45–54 0.2217 1.5550 <0.0001
55+ 0.4415 1.1056 <0.0001
Charlson comorbidity index score (vs Charlson comorbidity index score less than 1)
Between 1 and 2 0.8662 2.3779 <0.0001
Greater than 2 0.972 2.6432 <0.0001
Treatment naïve (vs treatment experienced) 0.1196 1.1270 0.0033
Had a mental disorder diagnosis (vs no mental disorder diagnosis) 0.256 1.2917 <0.0001
Had a drug or alcohol abuse diagnosis (vs no drug or alcohol abuse
diagnosis)
0.7109 2.0357 <0.0001
Length of follow-up (in days) 0.0013 1.0013 <0.0001
2+PPD; two or more pills per day; STR, once-daily single-tablet regimen.
Figure 2 Adjusted rate of hospitalisations per 100
patient-years, by cohort.
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analyses on hospitalisation rates for patients with no
baseline comorbidities as reported by CCI. We found
that the majority (∼70%) of STR and 2+PPD patients
had no other CCI comorbidities. Among STR patients
with no other comorbidities from CCI, 13.9% had a hos-
pitalisation compared with 18.3% of 2+PPD patients with
no other comorbidities. Further, among STR patients
with no comorbidities, 11.4% of adherent patients had a
hospitalisation compared with 14.7% of non-adherent
patients. Similarly, among 2+PPD patients with no
comorbidities, 12.4% of adherent patients had a hospi-
talisation compared with 19.7% of non-adherent
patients. The results of this sensitivity analysis, combined
with the observation that the vast majority of patients in
our study had no major comorbidities (from the CCI)
requiring other chronic treatment, suggest that the
observed association between poorer adherence and
higher hospitalisation was most likely due to reduced
ART adherence and not due to reduced adherence with
other medications that the patients were taking.
There were several measurable differences present in
the study population at baseline. Our study attempted to
control for effects these differences may have had on
rates of hospitalisation between STR and 2+PPD
patients. We used multivariate regressions to control for
patient demographics, treatment characteristics (ie,
treatment naïve vs experienced, type of ART received)
and clinical characteristics (ie, CCI score, concomitant
mental disorder, drug and alcohol abuse diagnoses). We
found that a number of factors were associated with an
increased risk of hospitalisation independent of the
treatment regimen, including having a CCI score greater
than 1; having a concomitant drug or alcohol abuse
diagnosis; having a concomitant mental health disorder;
being femaleand of older age; and being treatment
naïve.
Even after controlling for the factors noted above, we
still detected an independent association of regimen
type with hospitalisation rates and, in fact, observed an
increase in the apparent protective effect of STR based
on the predicted, adjusted hospitalisation rate derived
from the Poisson model (39.5/100 patients in the STR
group vs 51.2/100 patients in the 2+PPD group; see
ﬁgure 2). One possible explanation for this difference is
that the Poisson model corrected a substantial imbal-
ance in the proportion of patients who were treatment
naive at index (47.5% of STR patients vs 24.5% of
2+PPD patients). Lack of naivety to ART exposure has
been shown in some studies to be a positive predictor of
hospitalisation in HIV patients,22 perhaps because
approximately one-third of the HIV patients wait to seek
care until their disease has progressed to the point that
they need acute treatment.23 24 As noted in a recent
study by Metsch et al,25 these patients often obtain initial
care in emergency departments and hospital inpatient
wards, and they tend not to persist with follow-up out-
patient care. This pattern of treatment induction may
further increase their risk of infection and rehospitalisa-
tion in the short term. As being treatment naïve was
shown in our data to be predictive of hospitalisation, the
Poisson model’s adjustment for the over-representation
of treatment naivety in the STR group may therefore
have resulted in the larger difference between STR and
2+PPD in hospitalisations than observed in the crude,
unadjusted comparison.
One hypothesis for a plausible mechanism by which
the outcomes observed in our study could occur stems
from observations in the SMART study.26 That study,
comparing continuous antiviral treatment versus peri-
odic treatment interruptions, demonstrated that HIV
treatment interruptions that were of sufﬁcient length of
time to lead to recurrent HIV viraemia were associated
with a signiﬁcantly higher risk of all-cause morbidity and
mortality. Our analysis was consistent with those ﬁndings:
the mean maximum duration of non-adherence was
about 3 weeks, which is a sufﬁcient length of time to
expect a return of HIV viraemia. The SMART study
noted that the higher risk of illness was not necessarily
proximal to the time of the interruption but was
observed for months afterwards. While there are differ-
ences between the SMART study design and population
and our study population, our ﬁndings are consistent
with SMART and with what might be expected in a
population who periodically are without antivirals for an
average time of more than 3 weeks. Of note, short-cycle
Figure 3 Hospitalisations per 100 patient-years, by cohort
and adherence.
Figure 4 Adjusted monthly healthcare costs, by cohort.
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interruptions of 2 days were not associated with viro-
logical rebound in patients receiving the STR that was
used in the SMART study.27 Therefore, our ﬁnding that
the typical interruptions were much longer than this is
supportive of a mechanism that could have resulted in
increased patient morbidity.
It is also important to note that patients in this study
generally were reasonably adherent to ART, with a mean
adherence of just over 80% regardless of the number of
pills received per day. This rate of adherence is consist-
ent with other published reports of adherence, although
other reports found even higher adherence rates to an
STR.13 14 Furthermore, the difference observed in our
study between the STR and 2+PPD regimens (approxi-
mately 4%) is consistent with what was observed by Sax
et al16 of 2.2%. This difference is also consistent with the
differences in adherence rates reported when compar-
ing average improvement between once-daily and twice-
daily regimens (2.9%).28 It is important to note that
there also were highly non-adherent patients to both the
STR and the 2+PPD regimes in this study population,
supporting the generalisability of this population.
Of further note, the differences observed in our study
were associated with factors that typically are not present
during randomised clinical trials. Randomised trials typ-
ically actively work for patient adherence to study medi-
cations and use study coordinators to regularly monitor
patients to minimise missed doses. In our observational
study, these typical adherence supports are not in place;
thus, our data may reﬂect real-world lapses in patient
behaviour in reﬁlling prescriptions, including partial
regimen reﬁlls, which would not be observed in clinical
trials. While there are concerns about the interpretation
of observational data and the determination of causal
relationships, it is not clear if a randomised study com-
paring an STR with a multiple-pill regimen would be
able to detect the observed differences unless there was
less patient support than is standard in clinical trials.
Our data do not suggest that all patients should be on
an STR. There are many factors that weigh in the deci-
sion of which regimen is best for any given patient,
including pre-existing virological resistance and tolerabil-
ity. In our study, the anticipated adherence beneﬁts
observed in association with a lower pill burden is rele-
vant but should not be construed as a suggestion that an
STR is the ideal choice for the entire population of
patients with HIV. Nevertheless, our data do support the
continued development of additional STR options, to
broaden the number of patients for whom this is an
option and the number of subsequent beneﬁcial
outcomes.
Our study has several limitations common to observa-
tional claims database analyses. Adherence was calcu-
lated by using pharmacy reﬁll dates, and we have no
measure of actual patient adherence to the prescriptions
they ﬁlled. However, this measure has been found to be
a useful proxy for actual medication adherence.29 As we
did not randomise patients to the two different
treatment regimens, we cannot exclude unmeasured
confounding factors that may have inﬂuenced our out-
comes. Among the most important of these factors in
this study was that multiple trials have shown that medi-
cation resistance at the time of virological failure is sig-
niﬁcantly less common in boosted PI treatments than on
other regimens, including non-nucleoside/nucleotide
reverse transcriptase inhibitor-based treatments.30 31
Clinicians could have chosen to prescribe a boosted
PI-containing regimen (all of which contain three or
more pills per day) to their less-adherent patients.
It cannot be determined from this data set that these
patients would have been more adherent on an STR.
Although we attempted to control for some of these vari-
ables through the use of multivariable models that
included some of these factors (substance abuse and psy-
chiatric diagnoses), residual confounding may remain.
In addition, we had no laboratory results from patients
and thus cannot conﬁrm the degree of virological sup-
pression obtained across the regimens. Finally, although
our data include information from the Medicaid pro-
grammes in 11 states, the authors were blinded (as per
data privacy rules) as to which speciﬁc states are cap-
tured. Although the database’s documentation suggests
that the states are geographically dispersed, we cannot
assert that our ﬁndings would be fully representative of
the general Medicaid population in the USA.
In our study, a large proportion of HIV-treated indivi-
duals (15% of the total HIV-treated population) were
excluded from the analysis due to their having received
incomplete ART regimens. We did not have sufﬁcient
data on these patients to explain why their regimens
were incomplete. However, a previous study found that
the physician medication errors were somewhat
common in individuals with HIV, with the most common
error occurring with boosted PIs (estimated at 5.3% of
patients); such errors may explain some of the incom-
plete regimens observed in our analysis.32 Increased
adoption of ﬁxed-dose combinations as part of HIV
treatment may help to alleviate the issue of incomplete
regimens.
During our study period, the only available single-pill
ART regimen was coformulated efavirenz/emtricita-
bine/tenofovir disoproxil fumarate. It is possible that
these results would not be generalisable to other one-pill
and multipill regimens if other treatments have different
efﬁcacy and toxicity proﬁles. With the recent approval
by the Food and Drug Administration of two other STRs
(ie, tenofovir, emtricitabine and rilpivirine and tenofovir,
emtricitabine, elvitegravir and cobicistat), it may eventu-
ally be possible to explore the applicability of our obser-
vations to other STRs.
In summary, this study supported the results as reported
by Sax et al16 We found that patients who received ART as
a single pill per day were signiﬁcantly more likely to be
highly adherent to therapy than patients who received
multiple-pill regimens. This difference in adherence was
associated with a lower risk of hospitalisations: patients
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with less-than-complete adherence were more likely to
be hospitalised. While we acknowledge the limitations
associated with any observational study, our data support
our ﬁnding that the use of an STR may reduce
healthcare costs as well as patient morbidity by decreasing
hospitalisation rates, which are higher in patients with
less-than-complete medication adherence.
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